Here at Ipsen, we are committed to working with patients, for patients. As part of this commitment, we are pleased to share our first ever layperson clinical trial summary for the CLARINET clinical trial.
What is a layperson summary?
A layperson summary is just that, a document which clearly shares key information about a clinical trial in easy to understand language. These summaries are designed to improve data transparency making it simpler and easier for anyone without a medical background to find out more about our clinical trials.
The summary of the Phase III CLARINET trial is the first ever summary published by Ipsen, now available here.
Why is this important?
We are committed to making sure that we work with patients, for patients. By sharing layperson clinical trial summaries, we are working hard to ensure that information about the work we are doing and the research we are undertaking is clear and accessible to all. The CLARINET summary is the first we have shared but it won’t be the last. Make sure to keep an eye on the Patient section of our website for future trial summaries.
This initiative is part of a recent EMA data transparency policy, which asks companies to more clearly share clinical trial data. While we are not required to share these summaries for some time, we know the importance of making this information accessible for patients and have worked to generate this summary in collaboration with patients and lay people, and to share as soon as possible.
About the CLARINET trial
The CLARINET trial evaluated Somatuline® Autogel® (lanreotide Autogel) in non-functioning neuroendocrine tumors of the pancreas, intestines or unknown origin. These tumors, known as neuroendocrine tumors or NETs, are a rare group of slow growing tumors found in the digestive system which can often have no specific symptoms. Not all NETs can be removed using surgery, so medical treatments are often used to help control the growth and spread (progression) of the tumor. The CLARINET trial used a measure called progression-free survival (PFS), which calculates the time from the beginning of treatment until a patient has a sign that the disease has progressed, to see how effective Somatuline® Autogel® is.
Where can I find out more?
To learn more about the CLARINET clinical trial, follow this link to our summary, now available in the Patients section of Ipsen’s website.
